These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 34981056)

  • 21. Immunogenicity to SARS-CoV-2 Omicron variant among school-aged children with 2-dose of inactivated SARS-CoV-2 vaccines followed by BNT162b2 booster.
    Chantasrisawad N; Puthanakit T; Kornsitthikul K; Jaru-Ampornpan P; Tawan M; Matapituk P; Sophonphan J; Anugulruengkitt S; Tangsathapornpong A; Katanyutanon A;
    Vaccine X; 2022 Dec; 12():100221. PubMed ID: 36213592
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Levels and durability of neutralizing antibodies against SARS-CoV-2 Omicron and other variants after ChAdOx-1 or BNT162b2 booster in CoronaVac-primed elderly individuals.
    Takheaw N; Liwsrisakun C; Laopajon W; Pata S; Chaiwong W; Inchai J; Duangjit P; Pothirat C; Bumroongkit C; Deesomchok A; Theerakittikul T; Limsukon A; Tajarernmuang P; Niyatiwatchanchai N; Trongtrakul K; Kasinrerk W
    Heliyon; 2023 Apr; 9(4):e15653. PubMed ID: 37095993
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant.
    Edara VV; Lai L; Sahoo MK; Floyd K; Sibai M; Solis D; Flowers MW; Hussaini L; Ciric CR; Bechnack S; Stephens K; Mokhtari EB; Mudvari P; Creanga A; Pegu A; Derrien-Colemyn A; Henry AR; Gagne M; Graham BS; Wrammert J; Douek DC; Boritz E; Pinsky BA; Suthar MS
    bioRxiv; 2021 May; ():. PubMed ID: 34013272
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant.
    Zhou Z; Du P; Li N; Xiong X; Tang S; Dai Q; Wang T; Yu M; Man M; Lam K; Baptista-Hon DT; Tai WH; Monteiro O; Ng WS; Lee UM; Liu Z; Zhang K; Li G
    MedComm (2020); 2022 Jun; 3(2):e143. PubMed ID: 35592756
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlates of Neutralizing/SARS-CoV-2-S1-binding Antibody Response with Adverse Effects and Immune Kinetics in BNT162b2-Vaccinated Individuals.
    Maeda K; Amano M; Uemura Y; Tsuchiya K; Matsushima T; Noda K; Shimizu Y; Fujiwara A; Takamatsu Y; Ichikawa Y; Nishimura H; Kinoshita M; Matsumoto S; Gatanaga H; Yoshimura K; Oka SI; Mikami A; Sugiura W; Sato T; Yoshida T; Shimada S; Mitsuya H
    medRxiv; 2021 Jul; ():. PubMed ID: 34373860
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neutralizing antibody responses in vaccinated and unvaccinated individuals infected with Omicron BA.1 variant.
    Oh SJ; O SW; Choi YJ; Kim JM; Kim D; Kim IH; Park AK; Kim HM; Rhee JE; Jang YR; Yoo CK; Kim JY; Kim EJ
    J Clin Virol; 2022 Oct; 155():105253. PubMed ID: 35988369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neutralizing Antibodies Response against SARS-CoV-2 Variants of Concern Elicited by Prior Infection or mRNA BNT162b2 Vaccination.
    Bonura F; Genovese D; Amodio E; Calamusa G; Sanfilippo GL; Cacioppo F; Giammanco GM; De Grazia S; Ferraro D
    Vaccines (Basel); 2022 May; 10(6):. PubMed ID: 35746482
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles.
    Syed AM; Ciling A; Khalid MM; Sreekumar B; Chen PY; Kumar GR; Silva I; Milbes B; Kojima N; Hess V; Shacreaw M; Lopez L; Brobeck M; Turner F; Spraggon L; Taha TY; Tabata T; Chen IP; Ott M; Doudna JA
    medRxiv; 2022 Jan; ():. PubMed ID: 34981067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization.
    Planas D; Saunders N; Maes P; Guivel-Benhassine F; Planchais C; Buchrieser J; Bolland WH; Porrot F; Staropoli I; Lemoine F; Péré H; Veyer D; Puech J; Rodary J; Baele G; Dellicour S; Raymenants J; Gorissen S; Geenen C; Vanmechelen B; Wawina-Bokalanga T; Martí-Carreras J; Cuypers L; Sève A; Hocqueloux L; Prazuck T; Rey FA; Simon-Loriere E; Bruel T; Mouquet H; André E; Schwartz O
    Nature; 2022 Feb; 602(7898):671-675. PubMed ID: 35016199
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low Neutralizing Antibody Titers against the Mu Variant of SARS-CoV-2 in 31 BNT162b2 Vaccinated Individuals in Colombia.
    Álvarez-Díaz DA; Muñoz AL; Tavera-Rodríguez P; Herrera-Sepúlveda MT; Ruiz-Moreno HA; Laiton-Donato K; Franco-Muñoz C; Pelaez-Carvajal D; Cuellar D; Muñoz-Suarez AM; Galindo M; Arias-Ramírez EJ; Mercado-Reyes M
    Vaccines (Basel); 2022 Jan; 10(2):. PubMed ID: 35214639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Omicron Infection Evokes Cross-Protection against SARS-CoV-2 Variants in Vaccinees.
    Anichini G; Terrosi C; Gandolfo C; Gori Savellini G; Fabrizi S; Miceli GB; Franchi F; Cusi MG
    Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SARS-CoV-2 mRNA Vaccine Elicits Sustained T Cell Responses Against the Omicron Variant in Adolescents.
    Choi S; Kim SH; Han MS; Yoon Y; Kim YK; Cho HK; Yun KW; Song SH; Ahn B; Kim YK; Choi SH; Choe YJ; Lim H; Choi EB; Kim K; Hyeon S; Lim HJ; Kim BC; Lee YK; Choi EH; Shin EC; Lee H
    Immune Netw; 2023 Aug; 23(4):e33. PubMed ID: 37670807
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.
    Cameroni E; Saliba C; Bowen JE; Rosen LE; Culap K; Pinto D; VanBlargan LA; De Marco A; Zepeda SK; Iulio JD; Zatta F; Kaiser H; Noack J; Farhat N; Czudnochowski N; Havenar-Daughton C; Sprouse KR; Dillen JR; Powell AE; Chen A; Maher C; Yin L; Sun D; Soriaga L; Bassi J; Silacci-Fregni C; Gustafsson C; Franko NM; Logue J; Iqbal NT; Mazzitelli I; Geffner J; Grifantini R; Chu H; Gori A; Riva A; Giannini O; Ceschi A; Ferrari P; Cippà P; Franzetti-Pellanda A; Garzoni C; Halfmann PJ; Kawaoka Y; Hebner C; Purcell LA; Piccoli L; Pizzuto MS; Walls AC; Diamond MS; Telenti A; Virgin HW; Lanzavecchia A; Veesler D; Snell G; Corti D
    bioRxiv; 2021 Dec; ():. PubMed ID: 34931194
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitative and Qualitative Difference in Antibody Response against Omicron and Ancestral SARS-CoV-2 after Third and Fourth Vaccination.
    Hein S; Mhedhbi I; Zahn T; Sabino C; Benz NI; Husria Y; Renelt PM; Braun F; Oberle D; Maier TJ; Hildt C; Hildt E
    Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632552
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The SARS-CoV-2 Variant Omicron Is Able to Escape Vaccine-Induced Humoral Immune Responses, but Is Counteracted by Booster Vaccination.
    Hastert FD; Hein S; von Rhein C; Benz NI; Husria Y; Oberle D; Maier TJ; Hildt E; Schnierle BS
    Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632550
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased Receptor Affinity and Reduced Recognition by Specific Antibodies Contribute to Immune Escape of SARS-CoV-2 Variant Omicron.
    Vogt AS; Augusto G; Martina B; Chang X; Nasrallah G; Speiser DE; Vogel M; Bachmann MF; Mohsen MO
    Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632499
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and Immunogenicity of a Booster Vaccination by CoronaVac or BNT162b2 in Previously Two-Dose Inactivated Virus Vaccinated Individuals with Negative Neutralizing Antibody.
    Lai KT; Lai Wan Loong EY; Fung TL; Luk LW; Lau CC; Zee JS; Ma ES; Tang BS
    Vaccines (Basel); 2022 Apr; 10(4):. PubMed ID: 35455305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccine Protection Against the SARS-CoV-2 Omicron Variant in Macaques.
    Chandrashekar A; Yu J; McMahan K; Jacob-Dolan C; Liu J; He X; Hope D; Anioke T; Barrett J; Chung B; Hachmann NP; Lifton M; Miller J; Powers O; Sciacca M; Sellers D; Siamatu M; Surve N; VanWyk H; Wan H; Wu C; Pessaint L; Valentin D; Van Ry A; Muench J; Boursiquot M; Cook A; Velasco J; Teow E; Boon ACM; Suthar MS; Jain N; Martinot AJ; Lewis MG; Andersen H; Barouch DH
    bioRxiv; 2022 Feb; ():. PubMed ID: 35169798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
    Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
    Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibody response to SARS-CoV-2 mRNA vaccine in lung cancer patients: Reactivity to vaccine antigen and variants of concern.
    Valanparambil R; Carlisle J; Linderman S; Akthar A; Millett RL; Lai L; Chang A; McCook A; Switchenko J; Nasti T; Saini M; Andreas Wieland AW; Manning K; Ellis M; Moore K; Foster S; Floyd K; Davis-Gardner M; Viswanadh Edara V; Patel M; Steur C; Nooka A; Green F; Johns M; O Brein F; Shanmugasundaram U; Zarnitsyna V; Ahmed H; Nyhoff L; Mantus G; Garett M; Edupuganti S; Behra M; Antia R; Wrammert J; Suthar M; Dhodapkar M; Ramalingam S; Ahmed R
    medRxiv; 2022 Jan; ():. PubMed ID: 35018383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.